Deutsch
English
Español
Français
Nederlands
Português
Danish Pharma Giant Announces Major Restructuring
Novo Nordisk, the Danish pharmaceutical company behind the blockbuster weight-loss drugs Ozempic and Wegovy, has announced it will eliminate 9,000 jobs globally as it faces intense competition from American rivals. The company, which became Europe's most valuable listed company last year, is undergoing what it calls a "transformation to streamline the organization and enable faster decision-making."
Market Pressures Mount
The obesity drug market has become increasingly competitive, particularly in the United States where rival pharmaceutical companies have introduced similar but cheaper and more effective alternatives to Novo Nordisk's products. "The market is evolving, especially in obesity where competition has intensified and consumers have gained more influence," the company stated in its official press release.
Novo Nordisk's remarkable growth trajectory, driven by the unprecedented demand for its GLP-1 receptor agonists, has hit significant headwinds. The company's market capitalization had previously exceeded Denmark's entire GDP, contributing 1.7% to the Danish economy in 2024 alone.
Legal Battles and Supply Challenges
The Danish pharmaceutical giant has filed at least 130 lawsuits against competitors producing similar weight-loss medications. Additionally, the company has warned about shortages of key raw materials needed for production.
The job cuts come after a difficult period for Novo Nordisk. In July, the company issued a profit warning that wiped $70 billion from its market value. This was followed by the appointment of a new CEO and a hiring freeze implemented in August.
Impact on Workforce
Of the 9,000 positions being eliminated, approximately 5,000 will be in Denmark, where Novo Nordisk employs the majority of its 78,000-strong global workforce across 80 countries. The company maintains a Dutch operation with about 170 employees, though it remains unclear if they will be affected.
Novo Nordisk expects these layoffs to save approximately $1.2 billion by 2026. The company says it will focus on "growth opportunities" in diabetes and obesity treatments, likely referring to a new weight-loss pill awaiting approval for the US market. Current medications require injection administration.
Source: Novo Nordisk Press Release
Follow Discussion